A novel bispecific antibody able to pass the blood-brain barrier and therapeutically engage within the brain

Maj Schneider Thomsen; Torben Moos

doi:10.1016/j.medj.2022.11.006

A novel bispecific antibody able to pass the blood-brain barrier and therapeutically engage within the brain

Maj Schneider Thomsen, Torben Moos^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate › Research › peer-review

Abstract

The use of therapeutic antibodies for treating diseases in the CNS is hampered by the blood-brain barrier (BBB). In this issue, Edavettal et al.1 report on a novel bioengineered antibody not only capable of passing the BBB but also for intervening in pathological protein deposition and subsequent induction of clearing by microglia.

Original language	English
Journal	Med (New York, N.Y.)
Volume	3
Issue number	12
Pages (from-to)	815-817
Number of pages	3
ISSN	2666-6340
DOIs	https://doi.org/10.1016/j.medj.2022.11.006
Publication status	Published - 9 Dec 2022

Bibliographical note

Keywords

Antibodies, Bispecific/therapeutic use
Biological Transport
Blood-Brain Barrier/metabolism
Brain/metabolism

Access to Document

10.1016/j.medj.2022.11.006

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

@article{7347a0d693a9403f992ed32bec73c93f,

title = "A novel bispecific antibody able to pass the blood-brain barrier and therapeutically engage within the brain",

abstract = "The use of therapeutic antibodies for treating diseases in the CNS is hampered by the blood-brain barrier (BBB). In this issue, Edavettal et al.1 report on a novel bioengineered antibody not only capable of passing the BBB but also for intervening in pathological protein deposition and subsequent induction of clearing by microglia.",

keywords = "Antibodies, Bispecific/therapeutic use, Biological Transport, Blood-Brain Barrier/metabolism, Brain/metabolism",

author = "Thomsen, {Maj Schneider} and Torben Moos",

year = "2022",

month = dec,

day = "9",

doi = "10.1016/j.medj.2022.11.006",

language = "English",

volume = "3",

pages = "815--817",

journal = "Med (New York, N.Y.)",

issn = "2666-6340",

publisher = "Cell Press",

number = "12",

}

TY - JOUR

T1 - A novel bispecific antibody able to pass the blood-brain barrier and therapeutically engage within the brain

AU - Thomsen, Maj Schneider

AU - Moos, Torben

PY - 2022/12/9

Y1 - 2022/12/9

N2 - The use of therapeutic antibodies for treating diseases in the CNS is hampered by the blood-brain barrier (BBB). In this issue, Edavettal et al.1 report on a novel bioengineered antibody not only capable of passing the BBB but also for intervening in pathological protein deposition and subsequent induction of clearing by microglia.

AB - The use of therapeutic antibodies for treating diseases in the CNS is hampered by the blood-brain barrier (BBB). In this issue, Edavettal et al.1 report on a novel bioengineered antibody not only capable of passing the BBB but also for intervening in pathological protein deposition and subsequent induction of clearing by microglia.

KW - Antibodies, Bispecific/therapeutic use

KW - Biological Transport

KW - Blood-Brain Barrier/metabolism

KW - Brain/metabolism

U2 - 10.1016/j.medj.2022.11.006

DO - 10.1016/j.medj.2022.11.006

M3 - Comment/debate

C2 - 36495860

SN - 2666-6340

VL - 3

SP - 815

EP - 817

JO - Med (New York, N.Y.)

JF - Med (New York, N.Y.)

IS - 12

ER -

A novel bispecific antibody able to pass the blood-brain barrier and therapeutically engage within the brain

Abstract

Bibliographical note

Keywords

Access to Document

AUB Link

Fingerprint

Cite this